Results 11 to 20 of about 338,912 (243)

Myelodysplastic syndromes with ring sideroblasts (MDS‐RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN‐RS‐T) – “2021 update on diagnosis, risk‐stratification, and management”

American journal of hematology/oncology, 2021
Ring sideroblasts (RS) are erythroid precursors with abnormal perinuclear mitochondrial iron accumulation. Two myeloid neoplasms defined by the presence of RS, include myelodysplastic syndromes with RS (MDS‐RS) and MDS/myeloproliferative neoplasm with RS
M. Patnaik, A. Tefferi
semanticscholar   +1 more source

Inherited myeloproliferative neoplasm risk impacts hematopoietic stem cells

Nature, 2020
Myeloproliferative neoplasms (MPNs) are blood cancers that are characterized by the excessive production of mature myeloid cells and arise from the acquisition of somatic driver mutations in haematopoietic stem cells (HSCs).
Erik L. Bao, Satish K. Nandakumar, Xiaotian Liao, A. Bick, J. Karjalainen, M. Tabaka, O. Gan, A. Havulinna, T. Kiiskinen, C. Lareau, Aitzkoa L. Lapuente Portilla, Bo Li, C. Emdin, V. Codd, C. Nelson, C. Walker, C. Churchhouse, A. Chapelle, D. Klein, B. Nilsson, P. Wilson, Kelly Cho, S. Pyarajan, J. Gaziano, N. Samani, A. Regev, A. Palotie, B. Neale, J. Dick, P. Natarajan, C. O’Donnell, M. Daly, M. Milyavsky, S. Kathiresan, V. Sankaran, FinnGen, 23andMe Research Team   +36 more
semanticscholar   +2 more sources

Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN)

International Journal of Environmental Research and Public Health, 2021
Mutations of JAK2V617F, CALR, and MPL genes confirm the diagnosis of myeloproliferative neoplasm (MPN). This study aims to determine the genetic profile of JAK2V617F, CALR exon 9 Type 1 (52 bp deletion) and Type 2 (5 bp insertion), and MPL W515 L/K genes
R. H. Zulkeflee, Z. Zulkafli, M. F. Johan, A. Husin, Md. Asiful Islam, R. Hassan   +5 more
semanticscholar   +1 more source

Effects of ruxolitinib on infection in patients with myeloproliferative neoplasm: a meta-analysis

Hematology, 2021
Objective Infections in ruxolitinib-treated myeloproliferative neoplasm (MPN) patients were reported frequently. This work aimed to systematically estimate the risk of infection associated with ruxolitinib in MPN patients.
Qingsong Luo, Z. Xiao, Liming Peng
semanticscholar   +1 more source

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis

Leukemia, 2020
Myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) is characterized by cytopenias, marrow fibrosis, constitutional symptoms, extramedullary hematopoiesis, splenomegaly, and shortened survival.
M. Talpaz, J. Kiladjian
semanticscholar   +1 more source

Two-fold risk of pneumonia and respiratory mortality in individuals with myeloproliferative neoplasm: A population-based cohort study

EClinicalMedicine, 2020
Background: High cardiovascular comorbidity contributes to excess mortality in patients with myeloproliferative neoplasm, while less is known about respiratory comorbidity and mortality.
Kasper Mønsted Pedersen, Yunus Çolak, Hans Carl Hasselbalch, Christina Ellervik, Børge Grønne Nordestgaard, Stig Egil Bojesen   +5 more
doaj   +1 more source

Granulocytic sarcoma: Extramedullary manifestation of chronic myeloproliferative neoplasm in a young African woman

Human Pathology: Case Reports, 2021
We present a rare case of multiple granulocytic sarcoma in a young African woman in blast phase of chronic myeloproliferative neoplasm. Fine needle aspiration cytology of the sarcoma, peripheral blood film and bone marrow aspiration cytology were ...
Ajayi A. Ibijola, Abiodun I. Okunlola, Abiodun O. Awe   +2 more
doaj   +1 more source

A Case of Myeloproliferative Neoplasm-Associated Glomerulopathy in a Patient With Myelofibrosis. [PDF]

Clin Case Rep
ABSTRACT Myeloproliferative neoplasm (MPN)‐related glomerulopathy is a rare, late complication of MPN. Mesangial matrix expansion seems to be the histopathological hallmark. Proteinuria may not always be present. Further exploration is warranted to determine whether risk factors—including disease entity, mutation status and treatment regimens ...
Leibowitz S, Spanevello M, Francis L, Puri P, Hepburn K.   +4 more
europepmc   +2 more sources

Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase.

Blood Advances, 2020
Myeloproliferative neoplasms (MPN) that have evolved into accelerated or blast phase disease (MPN-AP/BP) have poor outcomes with limited treatment options and therefore represent an urgent unmet need.
J. Mascarenhas, R. Rampal, H. Kosiorek, Rupali Bhave, E. Hexner, E. Wang, A. Gerds, C. Abboud, M. Kremyanskaya, D. Berenzon, O. Odenike, N. Farnoud, A. Krishnan, R. Weinberg, E. McGovern, M. Salama, V. Najfeld, J. Medina-Martinez, J. A. Arango Ossa, M. Levine, Yangyu Zhou, L. Sandy, M. Heaney, R. Levine, R. Mesa, A. Dueck, R. Hoffman   +26 more
semanticscholar   +1 more source

Severe Dizziness and Hypereosinophilia: Coincidence or Complication? A Case Report

Case Reports in Oncology, 2020
Hypereosinophilia is a common issue in medicine. One rare cause is myeloproliferative neoplasm with PDGFRA rearrangement. In these patients, the gold standard for therapy is low-dose imatinib.
Giorgia Lo Presti, Beatrice Barda, Mario Uhr, Monika Raimondi, Oreste Mora   +4 more
doaj   +1 more source